Shortened Telomeres Linked to Muscle Degeneration in Duchenne, Study Finds

Utah Researcher Receives Grant to Study Stages of Congenital Myotonic Dystrophy

A University of Utah medical professor has received a $600,000 Muscular Dystrophy Association grant to conduct a clinical trial aimed at understanding how congenital myotonic dystrophy develops over time. The three-year grant will allow Dr. Nicholas Johnson, an assistant professor of neurology, pediatrics, and pathology, to study what scientists call the natural history…

First DMD Patients to Receive Raxone Under U.K.’s Early Access Program

The first patients with Duchenne muscular dystrophy (DMD) have been enrolled into the U.K.’s Early Access to Medicines Scheme (EAMS) for Santhera Pharmaceuticals’ Raxone (idebenone), giving patients access to the treatment before its regulatory approval. Raxone was included in EAMS after the Medicines and Healthcare Products Regulatory Agency (MHRA)…

Sarepta’s Exon 53 Skipping Therapy, Golodirsen, Improves Dystrophin Expression in Phase 1/2 Trial

Sarepta Therapeutics says its lead candidate therapy for exon 53 skipping, golodirsen, showed potential to treat Duchenne muscular dystrophy (DMD) in a first clinical trial of DMD patients. According to results of the Phase 1/2 clinical study, 4053-101 (NCT02310906), golodirsen significantly boosted dystrophin protein production in 25 boys with confirmed deletions…

4 People Who Have Something to Say About Muscular Dystrophy

These videos show how people living with muscular dystrophy (MD) can smash the stereotypes associated with having a disability, and lead rich and full lives. First up is 35-year-old Michael Klinkhamer, who has Becker muscular dystrophy. In this video shared by Story Hive, Michael explains that he spends all of…